My Great Grandma and Personalised Medicine

Death of Her Majesty Queen Elizabeth II

Find out more

Death of Her Majesty Queen Elizabeth II

The staff at Franks & Co were saddened to learn of the death of Her Majesty Queen Elizabeth II. Our thoughts are with His Majesty King Charles III and the rest of the Royal Family.

The United Kingdom is now officially in a period of mourning until after the Queen’s state funeral which is to be held on Monday 19 September. Normal day-to-day business will continue throughout this period.

The UK government has declared the day of the funeral to be a national Bank Holiday, so the United Kingdom Intellectual Property Office will be closed on Monday 19 September.

The United Kingdom Intellectual Property Office’s official guidance on bank holidays is given below:

The office is deemed to be closed on weekends, Good Friday, Christmas Day and all England and Wales bank holidays for all types of business, except for the filing of new applications not claiming priority. If documents are filed for these types of business at times when the office is deemed to be closed, they will receive an official filing date of the next working day.

Any official time period which expires on a weekend or any other day on which the office is closed is extended to the next working day.

Skip navigation

My great-grandmother died at the age of 93 in 1989. She irritated her GP by choosing only a part of the medication he prescribed.

She used to say: 'I feel this medicine is not good for me; that one is much better. I cannot say exactly why, but it is so.'

It seems that my great-grandmother was a pioneer of a new style of treatment, so called personalised medicine. In Europe, at least, the law has developed in a way that is favourable to patent applicants in the field of personalised medicine. The European Patent Office (EPO) has long recognised that a newly-discovered medical use of a known agent is patentable over the earlier use of the same agent. Through successive decisions of the Boards of Appeal (T836/01; T1642/06), this principle has developed to the point where identifying a new class of patient treatable using a known drug constitutes patentable subject matter.

Vanda Pichova, MSc.

European Patent Attorney

Article Published May 6, 2014